About 80% of breast cancers are ER+, meaning that the cancer cells have estrogen receptors, and estrogen is likely to make them grow. Here’s the good news/bad news story for ER+ MBC patients. First, the good news: there are a number of effective medications that either reduce available systemic estrogen or block its ability to stimulate cancer growth. The bad news: over time, ER+ cancers develop resistance to these medications, resulting in cancer progression and signaling the need for a new treatment.
Fortunately, there is more good news: the best minds in cancer research are on the case. In this episode, the Our MBC Life team hears from two dynamic MSK oncologists Dr. Pedram Razavi and Dr. Komal Jhaveri on treatment strategies and the latest research around the problem of endocrine resistance
Thanks for listening!
More info is available on our website:
Got something to share? Feedback?
Email: ourmbclife@sharecancersupport.org
Send us a voice recording via email or through speakpipe on our website. Follow us on Facebook, Instagram, and Twitter @ourmbclife.
We’re so happy you joined us! If this conversation resonated with you please share it with someone who might need it. Don't forget to like and subscribe here to follow us on your favorite podcast platform so you never miss an episode. You can find more episodes, resources and ways to get involved on our website Our MBC Life. Have a topic you’d like us to cover? Email us at ourmbclife@sharecancersupport.org. And don’t forget to follow us on our socials @ourmbclife.
Remember you are not alone.
